- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01030016
Study of Atenolol Influence on Blood Pressure During Resistance Exercise
December 14, 2009 updated by: University of Sao Paulo
Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers
The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.
Study Overview
Detailed Description
The study compared intra-arterial blood pressure responses during leg-extension resistance exercise performed to fatigue at 40, 80 and 100% of 1 RM in hypertensive patients receiving placebo (first) and atenolol (second) on a single blind manner.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
São Paulo, Brazil, 05508030
- University of Sao Paulo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- hypertension with blood pressure levels below 160/105 mmHg under placebo.
- age between 30 and 60 years
- nonobese
Exclusion Criteria:
- target organ lesion
- cardiovascular risk factor
- cardiovascular disease
- physically active
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: atenolol
subjects received 6 weeks of atenolol
|
25 mg/day, twice a day for 6 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
blood pressure during resistance exercise
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Cláudia LM Forjaz, PhD, University of Sao Paulo
- Study Chair: Decio Mion Jr, PhD, University of Sao Paulo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
May 1, 2009
Study Registration Dates
First Submitted
December 8, 2009
First Submitted That Met QC Criteria
December 9, 2009
First Posted (Estimate)
December 10, 2009
Study Record Updates
Last Update Posted (Estimate)
December 15, 2009
Last Update Submitted That Met QC Criteria
December 14, 2009
Last Verified
May 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Atenolol
Other Study ID Numbers
- FAPESP-06/06356-8
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.